Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PPIA | P62937 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468628 | 1.00 | HTT (0.51) | HTTMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2301534 | 0.83 | HTT (0.45) | HTTMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2301544 | 0.83 | HTT (0.45) | HTTMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6510650 | 0.81 | ALDH1A1 (0.44) | HTTMAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL4244032 | 0.80 | BRD4 (0.55) | MAPTCYP1A2CYP3A4CYP2D6MAPK1 | |
| SCHEMBL18640774 | 0.78 | DHODH (0.55) | HTTMAPTCYP1A2CYP3A4MAPK1 | |
| SCHEMBL26054502 | 0.78 | L3MBTL1 (0.49) | HTTMAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1577612 | 0.78 | TSHR (0.47) | HTTMAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL17520240 | 0.75 | ALDH1A1 (0.46) | HTTCYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL4254113 | 0.74 | TSHR (0.43) | HTTMAPTCYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068487-A1 | NEW HETEROCYCLIC COMPOUNDS BINDING TO SLC15A4 | SOLGATE GMBH (AT) | 2025-04-03 | — | — | WO | disclosed |
| CN-114716459-B | Carboxyl substituted ruthenium complex, preparation method and application thereof | 广州大学 | 2023-07-07 | — | — | CN | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2655342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| EP-2513109-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012087784-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-20090042928-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-12 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446112-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1709045-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20050171141-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-04 | — | — | US | disclosed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056552-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | HTT 1020/4885MAPT 3586/4885CYP1A2 2005/4885 |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | HTT 1338/4885MAPT 3355/4885CYP1A2 2390/4885 |
| US-20050171141-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | HTT 4097/4885MAPT 2360/4885CYP1A2 1408/4885 |
| US-20090042928-A1 | Modulators of muscarinic receptors | CHRM3, CHRM2, CHRM4 | HTT 4097/4885MAPT 2360/4885CYP1A2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.